Best Mike Calabrese Podcasts (2024)

1
MiniEp.03.5 Sailfish Migrations with The Billfish Foundation - A follow up to Ep.03 with Mike Calabrese 17:36

16d ago17:36

17:36

Join TBF Today!! https://billfish.org/become-a-member/ Be a part of TBF’s tagging program! https://billfish.org/research/tag-and-release/ Episode Summary In this mini episode of the Katie C. Sawyer podcast, Katie follows up on her previous chat about sail fishing in southern Florida with Mike Calabrese. She brings on Peter Chaibongsai and TJ Morrel…

1
Ep.04 John DePersenaire: Speed Reduction Zones in the North Atlantic 1:11:07

9d ago1:11:07

1:11:07

CONTACT YOUR LOCAL CONGRESSMAN: https://www.boatingunited.org/take-action/congress-protect-boaters-speed-restrictions/? Summary In this conversation, Katie C. Sawyer and John DePersenaire discuss the proposed rule for the North Atlantic right whale situation and its implications for boaters and seaboard communities. They highlight the importance of…

1
Ep. 03 Mike Calabrese: Kite vs. Dredge Fishing for Sailfish 1:14:47

23d ago1:14:47

1:14:47

In this conversation, Mike Calabrese discusses his history and experience in fisheries throughout the globe. He explains the technique of kite fishing in South Florida and the importance of bait culture. Mike also discusses the sailfish migration and their preferences for different types of bait. In this conversation, Mike Calabrese discusses the d…

1
Ep. 02 Chloe Mikles Discusses Bluefin Tuna Science 1:00:03

1M ago1:00:03

1:00:03

In this podcast episode, Katie interviews Chloe Mikles, a PhD student studying bluefin tuna. They discuss Chloe's research on bluefin tuna and blue marlin movement ecology and population structures. Chloe explains the process of tagging fish and the importance of tracking their migration patterns. Katie and Chloe also talk about the bluefin tuna fi…

1
E111: PEXIVAS Subsets with Mike Walsh & Mats Junek 39:27

1M ago39:27

39:27

At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer to his practice... but not all the way there. Longer podcast than usual but I prefer to release aud…

1
E110: Rheum4Debate - Screening for RA-ILD with Joshua Solomon and Scott Matson 24:19

2M ago24:19

24:19

Rheum4Debate is back! In this episode I moderated a debate between two pulmonologists about RA-ILD. As a reminder, Rheum4Debate is an Oxford-style debate show, where two debators disagree over a motion during 3 rounds of discussion. The motion for todays show was: “Asymptomatic patients with rheumatoid arthritis and high risk features for interstit…

1
Introduction to Katie and the Katie C. Sawyer Podcast 29:27

2M ago29:27

29:27

This episode is here to kick off the Katie C. Sawyer Podcast channel and give you, the listener, and idea of what you can expect moving forward. Katie didn't grow up in the fishing and hunting industry, so how did she end up living a life that completely revolves around it? Find out here.By Katie C. Sawyer

1
E109: Abatacept for Pre-RA - the ARIAA Study 16:22

2M ago16:22

16:22

Nice study this week on an important topic. Can we prevent the development of rheumatoid arthritis by initiating DMARDs during a preclinical phase? Lots to discuss: what does it mean to be "pre-clinical?" How does this fit with other studies of this nature? Check it out! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02650-8/ful…

1
E108: Myositis Guidelines for Cancer Screening w/Alexander Oldroyd 16:04

2M ago16:04

16:04

Informative podcast this week with Dr. Alexander Oldroyd, the first author of the recently published "International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening." The article itself appeared in Nature Reviews Rheumatology and provides what I think is a very useful framework for approaching this issue. Article: https://…

1
E107: Fragility of SLE Randomized Controlled Trials 13:17

3M ago13:17

13:17

Quick methodology episode this week discussing the concept of "fragility" in randomized controlled trials of lupus. Really enjoyed discussing this paper and was grateful to have been a part of it. Get the text here: https://lupus.bmj.com/content/lupusscimed/11/1/e001068.full.pdfBy Michael Putman

1
E106: GCA/PMR with Bhaskar Dasgupta 28:28

3M ago28:28

28:28

Today I'm taking another twitter discussion into the podcast realm! Dr. Bhaskar Dasgupta has published hundreds of papers about polymyalgia rheumatica and giant cell arteritis, including a recent publication in Nature Reviews: Rheumatology that piqued my interest (https://www.nature.com/articles/s41584-023-00976-8). In this podcast we discuss scree…

1
E105: Autoimmunity Post COVID-19? 17:41

4M ago17:41

17:41

Interesting topic and interesting paper this year, including discussion of observational biases, positive and negative controls, and interpreting data as it comes. Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810259By Michael Putman

1
E104: Sarilumab for PMR - The SAPHYR Study 18:35

5M ago18:35

18:35

Important trial on the podcast this week! I take a deep dive into the recently published SAPHYR study, which evaluated the use of the IL6 inhibitor sarilumab for patients with PMR. A few aggravating quibbles but overall a very useful trial and an important step forward for patients with PMR. Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2303…

1
E103: Len Calabrese on Monoclonal Antibodies for COVID-19 22:25

6M ago22:25

22:25

This week I took a twitter disagreement from the impersonal world of twitter to the podcast world of a back and forth conversation. Really enjoyed talking to Dr. Len Calabrese about monoclonal antibodies, FDA regulatory pathways, and life in general.By Michael Putman

1
E102: Unintentional Unblinding in Rheumatic Disease Trials 11:31

7M ago11:31

11:31

Excited to share an editorial that I wrote along with Cody Bruggemeyer and Desh Nepal, two trainees with me at the Medical College of Wisconsin. We discussed what I believe to be a pervasive (but seldom discussed) issue in rheumatology RCTs: unblinding. I suspect many of our studies suffer from this. Have a listen!…

1
E101: Pred v Colchicine for CPPD: COLCHICORT 10:49

7M ago10:49

10:49

Happy to share the FIRST randomized trial in CPPD today. It's kind of a weird study but worth a quick discussion. https://www.sciencedirect.com/science/article/pii/S2665991323001650By Michael Putman

1
E100: ADVOCATE Health Related Quality of Life 15:35

8M ago15:35

15:35

This week I dive into the health related quality of life measures that were reported in the ADVOCATE study. I found them overall somewhat convincing and they have affected my practice. Have a listen and be sure to follow along. Find my work at ebrheum.comBy Michael Putman

1
E99: Hospital Problems 7:29

8M ago7:29

7:29

Quick episode this week from a recent Perspective piece I had published in the New England Journal. Have a listen or a read! https://www.nejm.org/doi/full/10.1056/NEJMp2304828By Michael Putman

1
E98: Key Opinion Leaders & ILD Guidelines 10:29

8M ago10:29

10:29

Podcast this week discussing key opinion leaders (KOLs) and pharmaceutical companies. Please subscribe to my newsletter (ebrheum.com) and be sure to share the podcast with friends!By Michael Putman

1
E97: Does allopurinol reduce CVD? The ALLHEART Study 10:07

1y ago10:07

10:07

Nice quick RCT rundown this week, covering the ALLHEART study, a pragmatic RCT of urate lowering therapy to reduce cardiovascular disease. Quick listen for a useful teaching point! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01657-9/fulltextBy Michael Putman

1
E96: Long COVID - Where to After Norway? 19:38

1y ago19:38

19:38

Today I cover the recently published long-COVID study from Norway. It's a great paper that challenges much of the prevailing wisdom. I think there are some interesting limitations, but anyone who sees post COVID patients (aka all of us) would do well to read it. Or have a listen here! PDF: https://jamanetwork.com/journals/jamanetworkopen/fullarticl…

1
E95: Rituximab or Cyclophosphamide in ANCA Vasculitis 20:46

1y ago20:46

20:46

Fun study this week from JAMA Network Open and the French Vasculitis Study Group. They used a target trial emulation (one of my favorites) to ask whether RTX > CYC in AAV (another one of my favorites). I tried to use this to compare between observational and randomized data. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799018…

1
E94: Steroids and Psoriasis Flares 7:48

1y ago7:48

7:48

This week I hope to debunk one of rheumatology's "paradoxes." We love to talk about these and subject our fellows to memorizing them for the boards. We often use them to guide clinical practice, but I suspect that many "paradoxes" are actually the result of shoddy epidemiology. Todays' paper from JAMA dermatology covers one that I have heard freque…

1
E93: Azathioprine is the Worst 7:00

1y ago7:00

7:00

Today I'll be reading one of my recent newsletters! It's kind of a fun run-down of my anti-azathioprine stance. As I say in the piece, some patients may benefit from azathioprine and I am not saying it is an entirely useless drug or that nobody should ever prescribe it. Rather, I am just saying that it is likely the worst option for nearly every in…

1
E92: Are muscle symptoms from statins imaginary? 10:36

1y ago10:36

10:36

Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode! Paper: https://www.thelancet.com/article/S0140-6736(22)01545-8/fulltext "Internet driven cult" editorial: https://pubmed.ncbi.nlm.nih.gov/28…

1
E91: Clinical Innovation in Rheumatology: Past, Present, and Future 19:56

1+ y ago19:56

19:56

Change of pace today! I interviewed Jason Liebowitz and Phil Seo about their new book entitled "Clinical Innovation in Rheumatology: Past, Present, and Future." I thoroughly enjoyed the book and had a great time interviewing them about some of their "futuristic" topics. Grab the book (or better yet, have your division get some copies) at the link b…

1
E90: There Is No Diagnosis of Exclusion in Rheumatology 6:45

1+ y ago6:45

6:45

Quick episode this week to share an editorial I recently wrote with Jay Patel and Anisha Dua. We cover one of my least phrases in medicine, the "diagnosis of exclusion." Hope you enjoy! Find the original paper here: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keac278/6584804…

1
E89: Vitamin D to Prevent Osteoporotic Fractures 11:02

1+ y ago11:02

11:02

Exciting (negative) results from a large RCT on the podcast this week as well as a (mini) rant about how we should be spending our time as rheumatologists and the false security of ineffective treatments. Let me know what you think on twitter @ebhruem https://www.nejm.org/doi/full/10.1056/NEJMoa2202106…

1
E88: HCQ Dose Reductions and SLE Flares 10:04

1+ y ago10:04

10:04

Interesting case-crossover study today evaluating the association between HCQ dosing and risk of SLE flares. Super worth your time to read the paper or listen to this episode! https://jamanetwork.com/journals/jama/article-abstract/2796634By Michael Putman

1
E87: IVIG for Dermatomyositis 17:52

1+ y ago17:52

17:52

Podcast is back! This week I discuss a pivotal RCT in dermatomyositis. Check it out and be sure to subscribe to my newsletter at ebrheum.com!By Michael Putman

1
E86: Target Trials and Causality in Rheumatology 16:06

2y ago16:06

16:06

Mixing it up again this week to discuss an editorial by Miguel Hernan and a systematic review of target trials in rheumatology. It's kind of a fun free-form stream of consciousness. Hope you enjoy! Links: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888052/ https://pubmed.ncbi.nlm.nih.gov/32381560/By Michael Putman

1
E85: Challenging Wisely 7:58

2y ago7:58

7:58

Quick episode today. I wanted to share an editorial that was recently published in Rheumatology, where I and co-authors (Shannon Tai and Natalie Anumolu) discuss lessons from recent trials in AAV and SLE. Link to editorial: https://pubmed.ncbi.nlm.nih.gov/35438142/By Michael Putman

1
E84: The JAKapocalypse (AKA ORAL Surveillance) 12:24

2y ago12:24

12:24

After some delay, I finally get around to discussing ORAL-Surveillance, a post-marketing safety study of tofacitinib for rheumatoid arthritis. It's an incredibly important trial that will likely affect how all of us practice for the foreseeable future. Link to paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2109927…

1
E83: Effectiveness of COVID-19 Vaccines 19:00

2y ago19:00

19:00

After a winter hiatus, the podcast is back! Today I wanted to dive into a 'hotbutton' issue - the question of whether (or not) COVID-19 vaccines "work" for patients with rheumatic diseases. My answer is an emphatic "yes," albeit with a few caveats. Here are the papers I discuss: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)000…

1
E82: LoVAS Trial for ANCA Vasculitis 15:17

2+ y ago15:17

15:17

Hello again! Snappy episode this week about the exciting LoVAS trial, which compared a reduced dose steroid taper for ANCA vasculitis. Be sure to drop by my website at ebrheum.com to subscribe to my newsletter!By Michael Putman

1
E81: Vasculitis Guidelines E7: Takayasu Arteritis with Dr. Andy Abril 21:24

3y ago21:24

21:24

In this episode, I talk with Dr. Andy Abril, Chair at the Division of Rheumatology at the Mayo Clinic in Jacksonville Florida. Dr. Abril is one of the lead authors for the 2021 ACR Guidelines on Takayasu’s arteritis. This project was done in partnership with the Vasculitis Foundation. To review the complete guidelines, visit https://dev.vasculitisf…

1
E80: Vasculitis Guidelines E6 - Polyarteritis Nodosa with Dr. Jason Springer 19:37

3y ago19:37

19:37

In this episode, I talk with Dr. Jason Springer, Co-Director of the Vanderbilt Vasculitis Center, about the guidelines for PAN He is one of the lead authors for the ACR/VF Guidelines for Polyarteritis Nodosa. This project was done in partnership with the Vasculitis Foundation. To review the complete guidelines, visit https://dev.vasculitisfoundatio…

1
E79: Vasculitis Guidelines E5 - GCA with Dr. Mehrdad Maz 26:48

3y ago26:48

26:48

On today's episode I discuss GCA with Dr. Mehrdad Maz. He is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section and served on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines. We cover a lot of great topics! This project was done in partnership with the Vasculitis Foundation…

1
E78: Vasculitis Guidelines #4 - EGPA with Dr. Phil Seo 19:32

3y ago19:32

19:32

In today's episode, I talk with Dr. Mehrdad Maz about the newly published guidelines for giant cell arteritis (GCA). Dr. Maz is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section. He serves on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines. This project was done in partner…

1
E77: Vasculitis Guidelines #3 - ANCA Vasculitis with Dr. Sharon Chung 32:45

3y ago32:45

32:45

The guidelines have finally arrived! I'm kicking off the series today with a conversation about the ANCA vasculitis guidelines. My guest is Dr. Sharon Chung, the director of the UCSF Vasculitis Clinic and the lead investigator on the ACR/Guideline committee. She provided a LOT of great insights; have a listen and let us know what you think! This pr…

1
E76: Voclosporin for SLE Nephritis: The AURORA RCT 15:56

3y ago15:56

15:56

Hopping in this week to round out my thoughts on ADVOCATE (avacopan in AAV) and covering the recently published AURORA trial for SLE nephritis. Back to the Vasculitis Guidelines Podcast after as soon as they are released!By Michael Putman

1
E75: Vasculitis Guidelines Episode 2: Overview with Sharon Chung 21:53

3y ago21:53

21:53

In this episode we'll be introducing the process by which the 2021 ACR/VF guidelines were produced. My guest is Dr. Sharon Chung. She's the director of the UCSF Vasculitis Clinic and the lead investigator on the guideline committee. Please follow along with future episodes - you can find me @ebrheum and the Vasculitis Foundation is at @vasculitisfo…

1
E74: Vasculitis Guidelines Episode 1 - Joyce Kullman 10:32

3y ago10:32

10:32

Welcome to the first episode of the Vasculitis Guidelines Podcast! In Episode 1, I interview Joyce Kullman, Executive Director of the Vasculitis Foundation, about collaborating with the ACR in updating these guidelines, and how patients with vasculitis will ultimately benefit from them. We discuss the complex process of updating these critical guid…

1
E73: Introducing the Vasculitis Guidelines Podcast 1:41

3y ago1:41

1:41

Quick update on a new series!By Michael Putman

1
E72: Avacopan for ANCA Vasculitis 17:05

3y ago17:05

17:05

Steroid free remission! Or is it? This week I discuss a really exciting trial in ANCA vasculitis.By Michael Putman

1
E71: MTX Discontinuation Post... Influenza Vaccination 13:16

3+ y ago13:16

13:16

I stole some time to tackle a pressing issue for rheumatologists - to hold or not to hold immunosuppression in patients who are receiving a COVID19 vaccination. We obviously don't have any data on this, but I have always loved this study on influenza vaccination. PDFs at ebrheum.com/twts and follow me on twitter @ebrheum!…

1
E70: Rheum4Debate - HCQ Levels Should Be Monitored in Patients with SLE 37:37

3+ y ago37:37

37:37

We have a great show for you this week! Anisha Dua will be moderating a debate between myself and Max Konig on this motion: "Hydroxychloroquine levels should be monitored in patients with SLE." I learned a ton and thoroughly enjoyed it. Be sure to vote on the post-debate twitter poll to decide the winner!…

1
E69: Publication Trends in SRMAs and RCTs 7:10

3+ y ago7:10

7:10

This week I cover another of my meta-research projects, this one on systematic review and meta analysis (SRMA) growth as compared to randomized clinical trial (RCT) growth. Short and to the point - hope you enjoy! I highly recommend checking out the associated graphs - just take a quick peek at some point while listening. Find them on my twitter ha…

1
E68: SELECT-CHOICE Upadacitinib vs Abatacept in RA 13:39

3+ y ago13:39

13:39

Active comparator trial! Always my favorite. Lots of fun topics in this one, including noninferiority trials, crafty endpoints, and PROs. Check it out and let me know what you think! @ebrheumBy Michael Putman

1
E67: Belimumab in Lupus Nephritis (BLISS-LN) 15:38

3+ y ago15:38

15:38

Another day, another lupus trial, another round of endpoint shenanigans. Why does that matter? How big is the benefit from belimumab in SLE nephritis? Will this save lives and prevent ESRD / RRT? I try to tackle these issues this week and (hopefully) avoid getting myself in trouble. Hope you enjoy the episode! Let me know what you think @ebrheum on…

Podcasts Worth a Listen

Mike Calabrese Podcasts

Podcasts Worth a Listen

Quick Reference Guide